Is the PRECISE Score Reliable for Prostate Monitoring?

The PRECISE scoring system provides a standardized framework for evaluating serial MRI scans in prostate cancer patients. Doctors often use active surveillance for low-risk cases to avoid unnecessary treatments. Consequently, having a reliable tool to detect disease progression is absolutely essential. A recent international multicentre study validated these recommendations across 22 specialized centers. Therefore, researchers could confirm if radiological changes accurately correlate with future biopsy results.

The PRECISE Scoring System in Active Surveillance

The system categorizes radiological changes on a scale from 1 to 5. Specifically, PRECISE 1-2 indicates regression, while PRECISE 3 suggests stable disease. Furthermore, scores of 4-5 signal clear radiological progression. This study analyzed over 1,600 patients to test these important benchmarks. The results showed that patients with higher scores had a significantly increased risk of biopsy progression. This finding strongly supports the system’s role as a predictive clinical tool.

Clinical Accuracy and Key Validation Results

The data revealed a 4.53-fold increase in progression odds for those with PRECISE 4-5. Moreover, the negative predictive value for higher-grade cancer remained impressively high throughout the study. This means clinicians can safely monitor stable patients without immediate invasive intervention. However, radiologists must maintain high standards of reporting to ensure consistency. The multicentre nature of this study adds significant weight to these global findings. Therefore, urologists can confidently trust these scores for daily clinical decisions.

Frequently Asked Questions

Q1: What does a PRECISE 4 score indicate?

A PRECISE 4 score indicates radiological progression compared to previous scans, suggesting an increased risk of clinical cancer progression.

Q2: Is the PRECISE system useful for avoiding biopsies?

Yes, its high negative predictive value helps identify stable patients who might safely delay or avoid immediate follow-up biopsies.

References

1. Giganti F et al. Multicentre validation of the PRECISE scoring system for prostate MRI during active surveillance. Eur Radiol. 2026 May 04. doi: 10.1007/s00330-026-12570-z. PMID: 42080884.
2. Moore CM et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate. Eur Urol. 2013 Oct;64(4):544-52. doi: 10.1016/j.eururo.2013.03.030.
3. Schoots IG et al. Prostatic adherence to PRECISE in active surveillance of prostate cancer: a systematic review. Eur Radiol. 2021 Oct;31(10):7604-7613. doi: 10.1007/s00330-021-07851-4.